Previous 10 | Next 10 |
Today, we post our first analysis around Arbutus Biopharma. This small cap developmental concern is focusing on treating hepatitis B. The company is in the process of conducting several mid-stage trials with three different collaboration partners around its main drug candidate, AB-729...
Food manufacturers and general-merchandise retailers have faced challenges recently, with supply-chain disruptions complicating their ability to provide forecasts for the tail end of the year. But what about retailers who sell food? As it turns out, they've done very well lately. Thursday saw...
Gainers: Sphere 3D (NASDAQ:ANY) +50%. Data Storage (NASDAQ:DTST) +28%. Cloopen Group (NYSE:RAAS) +26%. Aurora Mobile (NASDAQ:JG) +21%. Liquid Media (NASDAQ:YVR) +21%. Globalstar (NYSE:GSAT) +20%. TSR (NASDAQ:TSRI) +19%. The L.S. Starrett (NYSE:SCX) +18%. Tiziana Life Sciences (NASDAQ:TLSA) +1...
Gainers: Innate Pharma (NASDAQ:IPHA) +32%, Tiziana Life Sciences (NASDAQ:TLSA) +16%, Verrica Pharmaceuticals (NASDAQ:VRCA) +12%, NeuroBo Pharmaceuticals (NASDAQ:NRBO) +12%, Scopus BioPharma (NASDAQ:SCPS) +11%. Losers: Assembly Biosciences (NASDAQ:ASMB) ...
Assembly Biosciences ASMB -19% after abandons development of phase 2 hepatitis b candidate ABVC BioPharma (NASDAQ:ABVC) -12%. Chewy CHWY -10% on Q2 earnings release American Eagle Outfitters AEO -9% on Q2 earnings release Five Below FIVE -8% on Q2 earni...
--Decision follows observation of elevated alanine transaminase (ALT) levels in Phase 2 study --Company will focus on advancing ongoing triple combination studies and earlier pipeline candidates SOUTH SAN FRANCISCO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Assembly Biosc...
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced it has selected a fourth core inhibitor candidate, ABI-4334 ...
Assembly Biosciences (NASDAQ:ASMB): Q2 GAAP EPS of -$0.55 beats by $0.11. Cash, cash equivalents and marketable securities of $199.1M Press Release For further details see: Assembly Biosciences EPS beats by $0.11
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent highlights for the second ...
Assembly Biosciences (NASDAQ:ASMB) announces the promotions of Jason Okazaki to chief operating officer and Michael Samar to chief financial officer. Okazaki joined Assembly Bio in 2020 as chief legal and business officer responsible for leading and executing strategi...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...